Cargando…

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class) and survival. Retrospective analysis of a multicenter, observational study of real clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Villaverde, Ricardo, Rodriguez Fernandez-Freire, Lourdes, Font-Ugalde, Pilar, Galan-Gutierrez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456674/
https://www.ncbi.nlm.nih.gov/pubmed/36079026
http://dx.doi.org/10.3390/jcm11175098
_version_ 1784785875217940480
author Ruiz-Villaverde, Ricardo
Rodriguez Fernandez-Freire, Lourdes
Font-Ugalde, Pilar
Galan-Gutierrez, Manuel
author_facet Ruiz-Villaverde, Ricardo
Rodriguez Fernandez-Freire, Lourdes
Font-Ugalde, Pilar
Galan-Gutierrez, Manuel
author_sort Ruiz-Villaverde, Ricardo
collection PubMed
description Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class) and survival. Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate-to-severe plaque psoriasis in treatment with TIL. This cross-sectional analysis includes information of patients between February 2019 to February 2022. A total of three tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using IBM SPSS v28 for Windows. A total of 61 patients were included in the analysis. The mean age of our patients was 49.5 years; 50.18% of the patients were female and 34.42% of the patients had a BMI greater than 30. It was notable that 44.26% of our patients had scalp involvement. Almost 35% of the patients had psoriatic arthropathy, although skin involvement was predominant. At week 52 (n = 34), 68% of the patients presented an absolute PASI equal to or less than 1. Regarding the drug survival, eight patients discontinued treatment due to inefficacy: five primary and three secondary failures, and one death due to causes not drug related showing survival of 86% at week 52. In the analysis of subgroups of patients, we found that scalp involvement determined greater survival (94%), as well as a shorter duration of the disease (91.7% vs. 84.4% in those with less than 10 years versus more than 15 years of evolution) and with a lower number of previous biological therapies (100% naïve, 90% in those who have used one line of biological therapy and 82.1% in those who have completed two or more lines of biological treatment. Tildrakizumab showed excellent results in the control of psoriasis in the mid-term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety or survival results of TIL between patients coming from previous therapies.
format Online
Article
Text
id pubmed-9456674
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94566742022-09-09 Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain) Ruiz-Villaverde, Ricardo Rodriguez Fernandez-Freire, Lourdes Font-Ugalde, Pilar Galan-Gutierrez, Manuel J Clin Med Article Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class) and survival. Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate-to-severe plaque psoriasis in treatment with TIL. This cross-sectional analysis includes information of patients between February 2019 to February 2022. A total of three tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using IBM SPSS v28 for Windows. A total of 61 patients were included in the analysis. The mean age of our patients was 49.5 years; 50.18% of the patients were female and 34.42% of the patients had a BMI greater than 30. It was notable that 44.26% of our patients had scalp involvement. Almost 35% of the patients had psoriatic arthropathy, although skin involvement was predominant. At week 52 (n = 34), 68% of the patients presented an absolute PASI equal to or less than 1. Regarding the drug survival, eight patients discontinued treatment due to inefficacy: five primary and three secondary failures, and one death due to causes not drug related showing survival of 86% at week 52. In the analysis of subgroups of patients, we found that scalp involvement determined greater survival (94%), as well as a shorter duration of the disease (91.7% vs. 84.4% in those with less than 10 years versus more than 15 years of evolution) and with a lower number of previous biological therapies (100% naïve, 90% in those who have used one line of biological therapy and 82.1% in those who have completed two or more lines of biological treatment. Tildrakizumab showed excellent results in the control of psoriasis in the mid-term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety or survival results of TIL between patients coming from previous therapies. MDPI 2022-08-30 /pmc/articles/PMC9456674/ /pubmed/36079026 http://dx.doi.org/10.3390/jcm11175098 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ruiz-Villaverde, Ricardo
Rodriguez Fernandez-Freire, Lourdes
Font-Ugalde, Pilar
Galan-Gutierrez, Manuel
Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
title Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
title_full Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
title_fullStr Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
title_full_unstemmed Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
title_short Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
title_sort tildrakizumab: efficacy, safety and survival in mid-term (52 weeks) in three tertiary hospitals in andalucia (spain)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456674/
https://www.ncbi.nlm.nih.gov/pubmed/36079026
http://dx.doi.org/10.3390/jcm11175098
work_keys_str_mv AT ruizvillaverdericardo tildrakizumabefficacysafetyandsurvivalinmidterm52weeksinthreetertiaryhospitalsinandaluciaspain
AT rodriguezfernandezfreirelourdes tildrakizumabefficacysafetyandsurvivalinmidterm52weeksinthreetertiaryhospitalsinandaluciaspain
AT fontugaldepilar tildrakizumabefficacysafetyandsurvivalinmidterm52weeksinthreetertiaryhospitalsinandaluciaspain
AT galangutierrezmanuel tildrakizumabefficacysafetyandsurvivalinmidterm52weeksinthreetertiaryhospitalsinandaluciaspain